Shots:
- PulseSight Therapeutics has dosed first pts in the P-I (PST-611-CT1) trial to assess safety & tolerability of PST-611 in humans
- The P-I single ascending dose study will evaluate safety & determine maximum tolerated dose of PST-611 for P-IIa trial in 6–12 pts with dry age-related macular degeneration/geographic atrophy pts, with preliminary results expected in early 2026, pending recruitment
- PST-611 is a non-viral vectorized therapy for dry AMD/GA that expresses human transferrin to restore iron homeostasis & treat disease pathology, with dosing needed only Q4M or Q6M
Ref: Globenewswire| Image: PulseSight| Press Release
Related News:- Cognition Therapeutics Reports Topline P-II (MAGNIFY) Trial Data of Zervimesine for Geographic Atrophy (GA)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
